Phase III ASPIRE Trial of Carfilzomib in Relapsed Multiple Myeloma
Overall survival results from the phase III ASPIRE trial will be detailed for the first time in an oral presentation by Stewart et al on Monday, December 11. The addition of carfilzomib to lenalidomide and dexamethasone significantly extended overall survival vs lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The safety data from ASPIRE were consistent with the known safety profile of carfilzomib.
Phase III MURANO Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia
Survival data from the phase III MURANO study by Seymour et al evaluating venetoclax tablets in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia will be presented on Tuesday, December 12, as an oral, late-breaking presentation.
First-in-Human Dose-Escalation Trial for CAR T-Cell Therapy
A first-in-human phase I dose-escalation clinical trial for CD123 chimeric antigen receptor (CAR) T cells is being presented on Monday, December 11, by Budde et al. The feasibility and safety of targeting CD123 have been demonstrated, and they observed antileukemic activity in patients with acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm—a rare and currently incurable blood cancer. No myeloablative effects were observed, and the authors support further testing of this strategy for these patients regardless of transplant eligibility status.
Multicenter Trial of CAR T-Cell Therapy for Refractory or Relapsed B-Cell NHL
Siddiqi et al will present their abstract on patient characteristics and biomarkers in the first multicenter phase I trial of JCAR017, a CAR T-cell therapy targeting CD19 cells in refractory or relapsed aggressive B-cell non-Hodgkin lymphoma (NHL).
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.